By Fineline Cube 
Jiangsu-based Contract Development and Manufacturing Organization (CDMO) Sinopep-Allsino Biopharmaceutical Co., Ltd (SHA: 688076) has signed a supply agreement with Gulf Pharmaceutical Industries, a UAE-based pharmaceutical company, for its semaglutide active pharmaceutical ingredients (APIs). This collaboration covers 22 countries in the Middle East and Africa (MEA), including the United Arab Emirates, Qatar, Saudi Arabia, Egypt, and Morocco.
Partnership Details
Sinopep-Allsino will provide Julphar with comprehensive support, including necessary documents and information for quality research and regulatory filing. The agreement also encompasses on-site technology transfer and technical assistance to address any technical challenges that may arise during the registration or production processes.
Market Expansion
This strategic partnership positions Sinopep-Allsino to leverage Julphar’s established commercial network in the region, facilitating entry into the promising MEA market. The collaboration underscores Sinopep-Allsino’s commitment to expanding its global presence and supporting regional pharmaceutical development through innovative solutions.-Fineline Info & Tech